Clinical trial
Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC
NCT00319800 · Gachon University Gil Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00319800 |
|---|---|
| Title | Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC |
| Official title | A Phase II Study of Second-Line Therapy With Irinotecan or Gefitinib in Docetaxel Pretreated Patients With Non-Small Cell Lung Cancer: a New Treatment Strategy According to Clinical Predictors for Response |
| Lead sponsor | Gachon University Gil Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, Irinotecan |
| Enrollment | 50 |
| Start date | Feb 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Apr 27, 2006 |
| Last update posted | Mar 12, 2008 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: